Page last updated: 2024-11-05

thioxanthone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thioxanthone is a tricyclic aromatic compound with a sulfur atom in the central ring. It is a yellow crystalline solid. It has been studied as a photosensitizer in photodynamic therapy for its potential to generate singlet oxygen. Thioxanthone derivatives are also known to have various biological activities, including anti-cancer, anti-inflammatory, and antimicrobial effects. Its synthesis involves various methods, including cyclization reactions and oxidation reactions. Thioxanthone is studied for its unique photophysical properties, such as its high quantum yield of singlet oxygen generation, which makes it a potential candidate for various applications.'

thioxanthone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10295
CHEMBL ID83371
SCHEMBL ID6916271
SCHEMBL ID36332
MeSH IDM0465672

Synonyms (58)

Synonym
AC-15767
CHEMBL83371 ,
NCI60_020340
nsc-658181
nsc-54677
nsc54677
thioxanthone
thioxanthene, 9-oxo-
9-thioxanthone
nsc15912
mls002638459 ,
492-22-8
thioxanthen-9-one
9h-thioxanthen-9-one
9h-thioxanthene, 9-oxo-
thiaxanthon
thiaxanthenone
thioxanthenone
10-thioxanthone
nsc-15912
thioxanthene-9-one
thiaxanthone
inchi=1/c13h8os/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8
nsc658181
thioxanthen-9-one, 97%
T2351
9-oxothioxanthene
smr000743848
bdbm50059265
cid_10295
AKOS001664685
HMS3089H20
SCHEMBL6916271
nsc 15912
nsc 658181
einecs 207-749-4
unii-eok1sac304
eok1sac304 ,
FT-0632221
thioxanthone [inci]
thioxanthone [mi]
SCHEMBL36332
DTXSID8060082
Q-201827
sr-01000504711
SR-01000504711-1
CS-0097787
mfcd00005066
thioxanthone, purum, >=97.0% (hplc)
F13552
thioxanthone, european pharmacopoeia (ep) reference standard
9h-thioxanthen-9-one (thioxanthone)
9h-thioxanthen-9-one; metixene hydrochloride imp. b (ep); thioxanthone; metixene hydrochloride impurity b; metixene impurity b
SY036813
Q2421313
9-oxothioxanthene,thioxanthone
EN300-1693738
Z1509688798

Research Excerpts

Effects

ExcerptReferenceRelevance
"Thioxanthone has been investigated extensively owing to its unique photochemical and photophysical applications and its solvatochromic behavior. "( Time-resolved resonance Raman spectroscopic studies on the triplet excited state of thioxanthone.
Pandey, R; Umapathy, S, 2011
)
2.04

Toxicity

ExcerptReferenceRelevance
" In conclusion, the study demonstrated the potential of the tested thioxanthonic compounds in protecting against toxic effects induced by P-gp substrates through P-gp induction and activation."( P-glycoprotein induction in Caco-2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity.
Barbosa, DJ; Bastos, Mde L; Carmo, H; Gameiro, M; Gomes, A; Paiva, AM; Palmeira, A; Pinto, M; RemiĆ£o, F; Silva, R; Sousa, E, 2015
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acid sphingomyelinaseHomo sapiens (human)Potency31.622814.125424.061339.8107AID504937
BRCA1Homo sapiens (human)Potency25.11890.89137.722525.1189AID624202
WRNHomo sapiens (human)Potency19.95260.168331.2583100.0000AID651768
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein skinhead-1Caenorhabditis elegansIC50 (µMol)65.05007.390021.523843.9000AID624474; AID651563
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID127028Inhibition of Monoamine oxidase B (MAO B) in rat brain at 10 uM1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Selective inhibitors of monoamine oxidase. 4. SAR of tricyclic N-methylcarboxamides and congeners binding at the tricyclics' hydrophilic binding site.
AID126044Inhibition of Monoamine oxidase A (MAO A) in rat brain.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Selective inhibitors of monoamine oxidase. 4. SAR of tricyclic N-methylcarboxamides and congeners binding at the tricyclics' hydrophilic binding site.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (19.35)18.7374
1990's1 (1.61)18.2507
2000's13 (20.97)29.6817
2010's29 (46.77)24.3611
2020's7 (11.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.22 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index5.80 (4.65)
Search Engine Demand Index54.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]